Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Clinical Trials: Around Half of… >
Clinical Trials: Around Half of New Treatments Perform Better Than Existing Treatments

Published: October 17, 2012.
By Wiley
http://www.wiley.com/wiley-blackwell

On average, new treatments perform better in clinical trials only slightly more often than existing treatments, according to a new systematic review published in The Cochrane Library. The fact that experimental treatments are not more effective may seem disappointing, but the authors of the review say their findings satisfy an important ethical requirement for clinical trials.

Randomised trials compare the effects of one treatment to another. In a randomised trial patients are randomly allocated to different treatment groups to ensure that like will be compared with like. When a new treatment is being tested, it is hoped or even expected that it will be better than the established treatment with which it is being compared. These expectations lead to an ethical dilemma. If the researchers already know that one treatment is better, they would be knowingly allocating some people to an inferior treatment. If randomised trials are to be ethical, therefore, only half of new treatments should turn out to be better than existing ones.

Cochrane researchers looked at evidence from 743 publicly funded randomised trials involving 297,744 patients in total. The trials included new, experimental treatments for cancer and neurological disorders, as well as a range of other diseases. On average, only very slightly more than half of new treatments proved to be better than established treatments.

"When we compared the effects of new treatments to established ones, the pattern was almost symmetrical. This is good news, because it means researchers genuinely don't know whether new treatments are going to be any better," said lead researcher Benjamin Djulbegovic, who works at USF Health Clinical Research, and the H. Lee Moffitt Cancer Center & Research Institute, at the University of South Florida in Tampa, Florida, US. "So, overall, what we show is that we can expect the new treatments to perform better a little bit more often than established treatments, at least in publicly funded trials like the ones we considered."

The researchers found the same pattern in trials going back five decades. The results provide an answer to the question posed 15 years ago in the British Medical Journal by Iain Chalmers, a founder of the Cochrane Collaboration and one of the authors of the review. "In 1997, in a letter published in the BMJ, I asked 'What is the prior probability of a proposed new treatment being superior to established treatments?' I think this review currently provides the best answer to that question," said Chalmers.




Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Trials 
8/27/13 
★ 
New Treatments Better Than Standard Ones Just over Half the Time
By University of South Florida (USF Health)
Tampa, FL (August 27, 2013) -- University of South Florida Distinguished Professor Benjamin Djulbegovic, MD, PhD, has studied the ethics of randomized clinical trials and their effectiveness in evaluating …
Society 
8/31/10 
CIHR Makes Recommendations on Canadian MS Research Priorities
By Canadian Institutes of Health Research
August 31, 2010 – On Thursday, August 26, the Canadian Institutes of Health Research (CIHR), in collaboration with the MS Society of Canada, convened a meeting of leading North …
Deaths 
6/18/14 
Death by Prescription Painkiller
By McGill University
The number of deaths involving commonly prescribed painkillers is higher than the number of deaths by overdose from heroin and cocaine combined, according to researchers at McGill University. In …
Bevacizumab 
9/15/14 
★★★★ 
Cheaper Alternative to Licensed Drug for Treating Eye Disease Has Similar Side-effects
By Wiley
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published …
Fenofibrate 
3/23/11 
Despite Uncertain Benefit, Fibrates Commonly Used in US, Canada
By JAMA and Archives Journals
Although recent evidence suggests that the clinical benefit may be uncertain for fibrates, a class of drugs used for the treatment of high lipid levels, use of these drugs …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition